We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Menu
Myeloma Center

You are here

Home > Research and Clinical Trials > Bibliography

Bibliography

Found 5 results
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
D
Dimopoulos MA, Terpos E, Niesvizky R.  2013.  How lenalidomide is changing the treatment of patients with multiple myeloma.. Crit Rev Oncol Hematol. 88 Suppl 1:S23-35.
Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A.  2015.  Clinical characteristics of patients with relapsed multiple myeloma.. Cancer Treat Rev. 41(10):827-35.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R et al..  2017.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. 18(10):1327-1337.